Key result
Long-term clopidogrel was more effective than medium-dose aspirin in reducing the combined risk of ischaemic stroke, MI, and vascular death in patients with atherosclerotic vascular disease.
Why the study?
Does long-term clopidogrel reduce the combined risk of ischaemic stroke, MI, and vascular death compared to medium-dose aspirin in patients with atherosclerotic vascular disease?
RCT
Does long-term clopidogrel reduce the combined risk of ischaemic stroke, MI, and vascular death compared to medium-dose aspirin in patients with atherosclerotic vascular disease?
Long-term clopidogrel is more effective than medium-dose aspirin for secondary prevention of ischemic events in patients with atherosclerotic vascular disease.
Answers are grounded in this paper and cite their sources.
May support clopidogrel over aspirin for secondary prevention; hypothesis-generating and requires randomized confirmation before practice change.
The long-term administration of clopidogrel to patients with atherosclerotic vascular disease – manifested as either recent ischaemic stroke, recent myocardial infarction (MI) or symptomatic peripheral arterial disease (PAD) – is more effective than the use of aspirin in reducing the combined risk of ischaemic stroke, MI and vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin.
No takes yet. Share an insight, caveat, or question.
Richard Donnelly (2005) conducted an RCT in Atherosclerotic vascular disease. Clopidogrel vs. Medium-dose aspirin was evaluated on Combined risk of ischaemic stroke, MI and vascular death. Long-term clopidogrel was more effective than medium-dose aspirin in reducing the combined risk of ischaemic stroke, MI, and vascular death in patients with atherosclerotic vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: